Arcturus Therapeutics (NASDAQ: ARCT)
Arcturus Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Arcturus Therapeutics Company Info
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
News & Analysis
Why Shares of Arcturus Therapeutics Dropped on Tuesday
The company saw revenue decline and net losses rise in the second quarter.
Why Arcturus Therapeutics Stock Is Soaring Today
Investors liked what they heard in its Q4 update.
Why Arcturus Therapeutics Stock Is Skyrocketing Today
Investors are applauding Arcturus' collaboration with CSL.
Could Arcturus Therapeutics Be the Next Moderna?
It's not likely, but it could still end up being a good investment.
Why Arcturus Therapeutics Stock Was Up 16% Thursday
The biotech stock climbed more than $5 a share in early trading Thursday.
Cathie Wood Just Bought Shares of This Vaccine Underdog. Should You?
The company disappointed last year, but things may be turning around.
Why Arcturus Therapeutics Stock Is Soaring Today
The company received a green light to advance two COVID-19 vaccine candidates into clinical testing in a second country.
Which Late-to-the-Party COVID Vaccine Stocks Could Still Be Winners?
There's at least one biotech that appears to be a potential contender.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.